Dyne Therapeutics Inc. (DYN) delivered some genuinely promising news Monday for patients with Duchenne muscular dystrophy, a devastating genetic disorder that progressively destroys muscle function. The biotech company released topline results from its Phase 1/2 DELIVER trial testing zeleciment rostudirsen (z-rostudirsen, or DYNE-251) in patients whose disease is amenable to exon 51 skipping.
Here's what matters: The trial's Registrational Expansion Cohort hit its primary endpoint, showing a statistically significant increase in muscle content-adjusted dystrophin expression to 5.46% of normal levels at six months. Dystrophin is the critical protein that muscles need for movement, and people with Duchenne muscular dystrophy don't produce enough of it. Getting dystrophin levels up is the whole ballgame.
These results mirror the 7-fold increase previously reported from the multiple-ascending dose portion of the same trial, which is encouraging because replication matters in drug development. When you see the same results twice, it's not a fluke.
How Does It Stack Up Against Current Treatment?
The comparison to existing therapy is striking. When measured without adjusting for muscle content, patients treated with 20 mg/kg z-rostudirsen every four weeks showed mean absolute dystrophin expression of 2.87% of normal. That's roughly 10 times higher than the 0.3% of normal reported in clinical trials of Sarepta Therapeutics Inc.'s (SRPT) Exondys 51 (eteplirsen), which is currently the weekly standard of care for DMD exon 51 in the United States.
Beyond the protein levels, the trial showed improvements across all six prespecified functional endpoints. Two measures in particular stood out: Time to Rise Velocity and 10-Meter Walk/Run Velocity both improved relative to placebo at six months with nominal statistical significance (p<0.05), even though the study wasn't designed or powered to demonstrate statistical significance in functional measures. That's essentially a bonus finding.
Perhaps most importantly, lung function measured by Forced Vital Capacity Percent Predicted remained stable at six months compared to a decline in the placebo group. This matters because lung function loss is a leading cause of death in Duchenne muscular dystrophy patients.
Safety Profile and Long-Term Data
Dyne also shared positive long-term clinical data from the ongoing open-label extension and long-term extension portions of the DELIVER trial. The drug maintained a favorable safety profile, with most related treatment-emergent adverse events classified as mild or moderate. The most common side effects were fever and headache, which is relatively manageable in the context of treating a progressive, life-threatening disease.
What Comes Next
The company plans to submit a Biologics License Application for U.S. Accelerated Approval in the second quarter of 2026, with a potential commercial launch in the first quarter of 2027. They're also planning to kick off a global Phase 3 clinical trial in the second quarter of 2026.
Investors seemed pleased with the news. Dyne Therapeutics shares were up 6.78% at $21.65 at the time of publication on Monday.
